this document is the first full description of the method of determining clinical breakpoints for antibiotics (for definition of terminology, see Clinical Microbiology and Infection, 1998; 4: 291-6) that has been used for the past 10 years by the European study Group on Breakpoints (ESGAB) and now to be used by EUCAST, its successor.